Opendata, web and dolomites

InDx SIGNED

InDx - an innovative implant that restores natural motion to patients with thumb base joint arthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 InDx project word cloud

Explore the words cloud of the InDx project. It provides you a very rough idea of what is the project "InDx" about.

human    germany    start    organization    investigations    university    world    biomechanics    substantial    approval    led    medvie    commercialisation    million    impossible    natural    dexterity    medical    endolab    final    ftes    validate    irish    causes    thumb    expertise    door    orthopaedics    approximately    fda    uk    51m    estimates    marking    arthritis    extensive    humanitarian    employment    fundamental    prepare    market    company    namsa    restore    clinical    trl    joint    implants    25    510k    launch    surgical    suffers    healthcare    anatomy    revenues    running    station    first    ireland    functional    accommodate    international    base    cumulative    dressed    stages    opening    treatment       usa    innovation    loci    debilitating    indx    dynamic    date    implant    sme    ce    commercialization    24    population    joints    prone    small    movement    galway    lags    stage    national    disruptive    europeans    jar    socioeconomic    designed    months    burden    spin   

Project "InDx" data sheet

The following table provides information about the project.

Coordinator
LOCI ORTHOPAEDICS LIMITED 

Organization address
address: UNIT 209 NUIG BUSINESS INNOVATION CENTRE UPPER NEWCASTLE
city: GALWAY
postcode: H91 V207
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙633˙125 €
 EC max contribution 2˙543˙187 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOCI ORTHOPAEDICS LIMITED IE (GALWAY) coordinator 1˙746˙500.00
2    NORTH AMERICAN SCIENCE ASSOCIATES LIMITED UK (SELBY) participant 319˙812.00
3    Medvie Limited IE (MALAHIDE) participant 280˙000.00
4    ENDOLAB MECHANICAL ENGINEERING GMBH DE (RIEDERING) participant 196˙875.00

Map

 Project objective

The thumb base joint is fundamental for human dexterity and functional activity but is prone to debilitating arthritis. Approximately 5% of the world population suffers from this condition with over 25 million Europeans affected. Simple tasks become impossible such as getting dressed, opening a jar, using a key to open a door. This is certainly a relevant socioeconomic and humanitarian concern, which causes a substantial cost burden on healthcare systems, yet the effective treatment for end-stage thumb base arthritis lags far behind other joints, given challenges of the small, complex anatomy. The InDx project aims to enable the commercialization of the InDx implant, the world’s first implant designed to accommodate the complex biomechanics of the thumb base joint and restore the natural movement of the thumb. The consortium is led by Loci Orthopaedics, a technology-driven SME spin-out company from the National University of Ireland, Galway. The partners include EndoLab in Germany, that has developed a novel dynamic test station for implants, NAMSA in the UK, a leading medical research organization with extensive experience in running international clinical investigations, and Medvie, an Irish based SME with extensive project management, dissemination and commercialization expertise. Together, the consortium have brought the implant to TRL 6 level. As part of the InDx project, the consortium will undertake the final stages of product development and will validate clinical results in a clinical study that will prepare the CE marking and market access. Market launch is planned within 24 months from the project start date, following FDA 510K approval in the USA and CE marking in Europe. The consortium estimates cumulative revenues of €51M within 5 years from the start of commercialisation and an employment growth of 25 FTEs for the consortium partners. The InDx has the potential to be a disruptive innovation in the surgical management of thumb base joint arthritis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INDX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INDX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

GoSafe (2019)

Restoring complete sensory ability for natural walking of amputees

Read More  

BIOSNAP (2019)

SMART, SUSTAINABLE & CONVENIENT UNIT DOSE PACKAGING

Read More  

Mag-ID (2019)

Magnetic identification

Read More